Track topics on Twitter Track topics that are important to you
AUSTIN, Texas, Aug. 12, 2015 (GLOBE NEWSWIRE) -- LDR Holding Corporation (NASDAQ:LDRH) ("LDR" or the "Company"), a global medical device company focused on designing and commercializing novel and proprietary spinal surgical technologies, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. LDR expects to grant the underwriters a 30-day option to purchase additional shares of its common stock.
LDR intends to use the net proceeds from the offering for (i) the continued expansion of its sales and marketing efforts in the United States and internationally, including its continued launch of Mobi-C in the United States, (ii) investments in research and development, (iii) potential acquisitions of complementary technologies, (iv) the repayment of approximately $18.2 million of debt and (v) working capital and other general corporate purposes.
Piper Jaffray and William Blair are acting as joint book-running managers for the offering.
The offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-199882) that was initially filed with the U.S. Securities and Exchange Commission (the "SEC") on November 5, 2014. A preliminary prospectus supplement describing the terms of the offering will be filed with the SEC and will form a part of the effective registration statement and will be available on the SEC's website located at www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained from the offices of Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at firstname.lastname@example.org and William Blair & Company, L.L.C. at 222 West Adams Street, Chicago, IL 60606, Attention: Prospectus Department, by telephone at 800-621-0687, or by email at email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About LDR Holding Corporation
LDR Holding Corporation is a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders. LDR's primary products are based on its exclusive VerteBRIDGE® fusion and Mobi® non-fusion technology platforms and are designed for applications in the cervical and lumbar spine. These technologies are designed to enable products that are less invasive, provide greater intra-operative flexibility, offer simplified surgical techniques and promote improved clinical outcomes for patients as compared to existing alternatives. In August 2013, LDR received approval from the U.S. Food and Drug Administration (FDA) for the Mobi-C cervical disc replacement device, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease.
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief or current expectations of LDR and members of its management team with respect to LDR's future business operations as well as the assumptions upon which such statements are based, and statements pertaining to LDR's expectations regarding the proposed public offering and the intended use of the proceeds from the offering. Actual results could differ materially from those anticipated due to certain risks and uncertainties including, without limitation, risks and uncertainties related to fluctuations in the Company's stock price, changes in market conditions and satisfaction of customary closing conditions related to the proposed public offering. There can be no assurance that LDR will be able to complete the proposed public offering on the anticipated terms, or at all. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in LDR's Risk Factors disclosure in its Annual Report on Form 10-K, in its Quarterly Reports on Form 10-Q, and in its other filings with the Securities and Exchange Commission as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the offering. LDR disclaims any responsibility to update any forward-looking statements.
CONTACT: Robert McNamara Executive Vice President and Chief Financial Officer LDR Holding Corporation (512) 344-3333 Matthew Norman Director, Investor Relations LDR Holding Corporation (512) 344-3408NEXT ARTICLE
The role of medical devices in healthcare is essential. The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare. Covering a wide range of products, from simple bandages to the...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...